Scancell Holdings Plc, (AIM:SCLP), the developer of novel immunotherapies for the treatment of cancer, today announces that interim data from its Immunobody® (SCIB1) Phase I/II clinical trial in patients with Stage III/IV melanoma will be presented at the upcoming American Association for Cancer Research annual meeting (AACR) in San Diego, California, 5-9 April 2014.

Dr Lindy Durrant, Joint CEO of Scancell, will present results from the clinical study in the AACR Conference Session CT331 “Immunotherapeutic Trials, Immune Response to Targeted Agents, and Prevention” which is scheduled to be held between 1pm and 3pm PDT on Tuesday, 8 April 2014.

AACR is the premier cancer research event with about 18,000 researchers, patient advocates, and other professionals in the cancer field from around the world scheduled to be in attendance. It provides a unique opportunity for members of the worldwide cancer research community to learn about cutting-edge advances, obtain feedback on their own research, and make connections that will foster future collaborations. The theme for this year’s meeting, “Harnessing Breakthroughs – Targeting Cures,” reflects the fact that the translation of basic science into clinical advances for the benefit of cancer patients is occurring at an increasing pace and more seamlessly than ever before.

All abstracts and details on timings can be accessed through the AACR website: http://www.aacr.org/home/scientists/meetings--workshops/aacr-annual-meeting-2014.aspx

The title, timing and location of the poster presentations are as follows:

For Further Information:

About Scancell

Scancell is developing novel immunotherapies for the treatment of cancer based on its ImmunoBody® and Moditope® technology platforms.  Scancell’s first ImmunoBody®, SCIB1 is being developed for the treatment of melanoma and is being evaluated in a Phase 1/2 clinical trial.  Data from the trial demonstrate that SCIB1 produced a melanoma-specific immune response and promising survival trend. 

Scancell’s ImmunoBody® vaccines target dendritic cells and stimulate both parts of the cellular immune system; the helper cell system where inflammation is stimulated at the tumour site; and the cytotoxic T-lymphocyte or CTL response where immune system cells are primed to recognise and kill specific cells.

Scancell has also identified and patented a series of modified epitopes that stimulate the production of killer CD4 that destroy tumours without toxicity.  The Directors believe that the Moditope® platform could play a major role in the development of safe and effective cancer immunotherapies in the future.